NASDAQ:VOR Vor Biopharma (VOR) Stock Price, News & Analysis $22.34 -0.90 (-3.87%) Closing price 04:00 PM EasternExtended Trading$22.08 -0.25 (-1.14%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Vor Biopharma Stock (NASDAQ:VOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vor Biopharma alerts:Sign Up Key Stats Today's Range$22.09▼$23.0950-Day Range$17.34▼$25.1052-Week Range$6.50▼$49.95Volume689,348 shsAverage Volume683,121 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$43.38Consensus RatingModerate Buy Company Overview Vor Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability. The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Preclinical studies have demonstrated selective resistance of edited HSCs to CD33-directed therapies, allowing concurrent administration of anti-CD33 agents to eliminate malignant cells while preserving healthy hematopoiesis. In addition to VOR33, Vor maintains a discovery pipeline of follow-on candidates targeting other hematologic cancer antigens, as well as programs exploring combination strategies with existing immunotherapies. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vor Biopharma went public in 2021 and collaborates with leading academic medical centers and contract development organizations across the United States. The company is led by President and Chief Executive Officer Sean Nolan, whose previous experience includes senior leadership roles in immuno-oncology and cell therapy development. Vor’s scientific advisory board comprises experts in hematology, stem cell biology, and genome editing, supporting its mission to transform the treatment paradigm for blood cancer patients.AI Generated. May Contain Errors. Read More Vor Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreVOR MarketRank™: Vor Biopharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 655th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingVor Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVor Biopharma has a consensus price target of $43.38, representing about 94.2% upside from its current price of $22.34.Amount of Analyst CoverageVor Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Vor Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vor Biopharma are expected to decrease in the coming year, from ($2.56) to ($3.43) per share. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.99% of the float of Vor Biopharma has been sold short.Short Interest Ratio / Days to CoverVor Biopharma has a short interest ratio ("days to cover") of 10.37, which indicates bearish sentiment.Change versus previous monthShort interest in Vor Biopharma has recently increased by 4.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.67 News SentimentVor Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Vor Biopharma this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,207.00 in company stock.Percentage Held by Insiders0.27% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VOR Stock News HeadlinesVor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9 at 9:00 PM | seekingalpha.comVor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia GravisSeptember 8 at 8:31 AM | marketscreener.comMWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 10 at 1:00 AM | Awesomely (Ad)Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia GravisSeptember 8 at 7:00 AM | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comVor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 3, 2026 | americanbankingnews.comVor Bio To Participate in Upcoming September ConferencesSeptember 1, 2026 | globenewswire.comVor Biopharma Shares Drop After Q2 ResultsAugust 11, 2026 | finance.yahoo.comSee More Headlines VOR Stock Analysis - Frequently Asked Questions How have VOR shares performed this year? Vor Biopharma's stock was trading at $13.08 at the beginning of the year. Since then, VOR shares have increased by 70.8% and is now trading at $22.34. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NASDAQ:VOR) released its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by $0.11. When did Vor Biopharma's stock split? Vor Biopharma shares reverse split on Thursday, September 18th 2025.The 1-20 reverse split was announced on Thursday, September 18th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $167 million in an initial public offering on Friday, February 5th 2021. The company issued 9,828,017 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO. Who are Vor Biopharma's major shareholders? Top institutional shareholders of Vor Biopharma include Braidwell LP (0.97%), Bank of New York Mellon Corp (0.18%), Engineers Gate Manager LP (0.06%) and Wellington Management Group LLP (0.05%). Insiders that own company stock include Ra Capital Management, LP and Reprogrammed Interchange Llc. View institutional ownership trends. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/10/20262026 Global Healthcare Conference9/15/2026Stifel 2026 Virtual Immunology and Inflammation Forum9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VOR's financial health is in the Green zone, according to TradeSmith. VOR has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VOR Previous SymbolNASDAQ:VOR CIK1817229 Webvorbio.com Phone(617) 655-6580FaxN/AEmployees140Year Founded2016Price Target and Rating Average Price Target for Vor Biopharma$43.38 High Price Target$64.00 Low Price Target$27.00 Potential Upside/Downside+94.2%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares59,160,000Free Float59,002,000Market Cap$1.32 billion OptionableN/A Beta1.71 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:VOR) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
